vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and AMREP CORP. (AXR). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $14.6M, roughly 1.4× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -541.1%, a 562.7% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs 86.1%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs -13.6%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
AGIO vs AXR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $14.6M |
| Net Profit | $-108.0M | $3.1M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | 20.6% |
| Net Margin | -541.1% | 21.6% |
| Revenue YoY | 86.1% | 93.8% |
| Net Profit YoY | -11.9% | 338.9% |
| EPS (diluted) | $-1.86 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.6M | ||
| Q4 25 | $20.0M | $9.4M | ||
| Q3 25 | $12.9M | $17.9M | ||
| Q2 25 | $12.5M | $11.2M | ||
| Q1 25 | $8.7M | $7.5M | ||
| Q4 24 | $10.7M | $11.9M | ||
| Q3 24 | $9.0M | $19.1M | ||
| Q2 24 | $8.6M | $19.5M |
| Q1 26 | — | $3.1M | ||
| Q4 25 | $-108.0M | $1.2M | ||
| Q3 25 | $-103.4M | $4.7M | ||
| Q2 25 | $-112.0M | $3.9M | ||
| Q1 25 | $-89.3M | $717.0K | ||
| Q4 24 | $-96.5M | $4.0M | ||
| Q3 24 | $947.9M | $4.1M | ||
| Q2 24 | $-96.1M | $4.1M |
| Q1 26 | — | — | ||
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — |
| Q1 26 | — | 20.6% | ||
| Q4 25 | -608.9% | 11.9% | ||
| Q3 25 | -907.4% | 34.4% | ||
| Q2 25 | -1020.1% | 31.7% | ||
| Q1 25 | -1222.0% | 5.7% | ||
| Q4 24 | -1165.3% | 26.4% | ||
| Q3 24 | -1146.9% | 26.1% | ||
| Q2 24 | -1228.3% | 23.9% |
| Q1 26 | — | 21.6% | ||
| Q4 25 | -541.1% | 12.8% | ||
| Q3 25 | -803.1% | 26.3% | ||
| Q2 25 | -899.4% | 34.8% | ||
| Q1 25 | -1023.3% | 9.5% | ||
| Q4 24 | -899.6% | 33.9% | ||
| Q3 24 | 10574.7% | 21.3% | ||
| Q2 24 | -1115.7% | 21.2% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | $-1.86 | $0.22 | ||
| Q3 25 | $-1.78 | $0.87 | ||
| Q2 25 | $-1.93 | $0.73 | ||
| Q1 25 | $-1.55 | $0.13 | ||
| Q4 24 | $-1.44 | $0.75 | ||
| Q3 24 | $16.22 | $0.76 | ||
| Q2 24 | $-1.69 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $50.0M |
| Total DebtLower is stronger | — | $21.0K |
| Stockholders' EquityBook value | $1.2B | $139.4M |
| Total Assets | $1.3B | $143.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | $89.1M | $44.6M | ||
| Q3 25 | $92.7M | $48.9M | ||
| Q2 25 | $80.9M | $39.5M | ||
| Q1 25 | $79.0M | $36.9M | ||
| Q4 24 | $76.2M | $40.1M | ||
| Q3 24 | $253.7M | $40.4M | ||
| Q2 24 | $84.5M | $29.7M |
| Q1 26 | — | $21.0K | ||
| Q4 25 | — | $23.0K | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | $26.0K | ||
| Q1 25 | — | $29.0K | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | — | $34.0K | ||
| Q2 24 | — | $35.0K |
| Q1 26 | — | $139.4M | ||
| Q4 25 | $1.2B | $136.0M | ||
| Q3 25 | $1.3B | $134.7M | ||
| Q2 25 | $1.4B | $130.0M | ||
| Q1 25 | $1.5B | $126.0M | ||
| Q4 24 | $1.5B | $125.1M | ||
| Q3 24 | $1.6B | $122.2M | ||
| Q2 24 | $660.5M | $118.0M |
| Q1 26 | — | $143.9M | ||
| Q4 25 | $1.3B | $140.1M | ||
| Q3 25 | $1.4B | $140.7M | ||
| Q2 25 | $1.5B | $133.8M | ||
| Q1 25 | $1.6B | $128.9M | ||
| Q4 24 | $1.7B | $129.1M | ||
| Q3 24 | $1.8B | $127.0M | ||
| Q2 24 | $773.1M | $122.8M |
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $5.4M |
| Free Cash FlowOCF − Capex | $-97.3M | $5.4M |
| FCF MarginFCF / Revenue | -487.5% | 37.0% |
| Capex IntensityCapex / Revenue | 5.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $20.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-96.2M | $-4.3M | ||
| Q3 25 | $-88.2M | $9.5M | ||
| Q2 25 | $-77.1M | $10.2M | ||
| Q1 25 | $-111.5M | $-3.2M | ||
| Q4 24 | $-133.2M | $-182.0K | ||
| Q3 24 | $-84.2M | $10.7M | ||
| Q2 24 | $-72.6M | $10.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-97.3M | $-4.3M | ||
| Q3 25 | $-89.7M | $9.5M | ||
| Q2 25 | $-78.0M | $9.7M | ||
| Q1 25 | $-112.3M | $-3.3M | ||
| Q4 24 | $-134.1M | $-268.0K | ||
| Q3 24 | $-84.6M | $10.7M | ||
| Q2 24 | $-72.7M | $10.3M |
| Q1 26 | — | 37.0% | ||
| Q4 25 | -487.5% | -45.9% | ||
| Q3 25 | -696.5% | 53.2% | ||
| Q2 25 | -626.2% | 86.4% | ||
| Q1 25 | -1286.4% | -43.4% | ||
| Q4 24 | -1250.1% | -2.3% | ||
| Q3 24 | -944.2% | 55.8% | ||
| Q2 24 | -844.4% | 52.5% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | 5.6% | 0.6% | ||
| Q3 25 | 12.1% | 0.1% | ||
| Q2 25 | 7.0% | 5.2% | ||
| Q1 25 | 8.8% | 0.3% | ||
| Q4 24 | 9.0% | 0.7% | ||
| Q3 24 | 4.7% | 0.2% | ||
| Q2 24 | 1.8% | 2.3% |
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | -0.09× | 2.63× | ||
| Q2 24 | — | 2.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
